MA49123A - Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers - Google Patents

Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers

Info

Publication number
MA49123A
MA49123A MA049123A MA49123A MA49123A MA 49123 A MA49123 A MA 49123A MA 049123 A MA049123 A MA 049123A MA 49123 A MA49123 A MA 49123A MA 49123 A MA49123 A MA 49123A
Authority
MA
Morocco
Prior art keywords
peptides
cancers
combination
immunotherapy against
against leukemia
Prior art date
Application number
MA049123A
Other languages
English (en)
Inventor
Marco Moreno Di
Sebastian Haen
Daniel Kowalewski
Markus Löffler
Annika Nelde
Hans-Georg Rammensee
Stefan Stevanovic
Nico Trautwein
Juliane Sarah Walz
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA49123A publication Critical patent/MA49123A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
MA049123A 2017-04-10 2018-04-10 Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers MA49123A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483690P 2017-04-10 2017-04-10
DE102017107710 2017-04-10

Publications (1)

Publication Number Publication Date
MA49123A true MA49123A (fr) 2020-03-25

Family

ID=62116820

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049123A MA49123A (fr) 2017-04-10 2018-04-10 Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers

Country Status (18)

Country Link
US (2) US20220118016A1 (fr)
EP (1) EP3609531A2 (fr)
JP (1) JP7026970B2 (fr)
KR (1) KR20190137858A (fr)
CN (3) CN110944660A (fr)
AU (1) AU2018253341B2 (fr)
BR (1) BR112019021094A2 (fr)
CA (1) CA3059645A1 (fr)
CL (7) CL2019002878A1 (fr)
CO (1) CO2019012071A2 (fr)
CR (1) CR20190509A (fr)
IL (1) IL269813A (fr)
MA (1) MA49123A (fr)
MX (1) MX2019012226A (fr)
MY (1) MY197772A (fr)
PE (1) PE20191617A1 (fr)
PH (1) PH12019502300A1 (fr)
SG (3) SG11201909058WA (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3079707A4 (fr) * 2013-12-02 2017-10-18 RXi Pharmaceuticals Corporation Immunothérapie du cancer
MX2019008844A (es) * 2017-01-26 2019-09-10 Sangamo Therapeutics Inc Ingenieria de celulas b.
JP2020530759A (ja) * 2017-07-07 2020-10-29 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用
CN113109564A (zh) * 2021-03-15 2021-07-13 成都益安博生物技术有限公司 一种急性髓细胞性白血病的外周血tcr标志物及其检测试剂盒和应用
CN117586344A (zh) * 2022-08-12 2024-02-23 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
CN117552115B (zh) * 2024-01-12 2024-03-26 天津鲸鹏生物科技有限责任公司 用于诱导肿瘤特异性免疫响应的通用型抗原肽库及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005561A1 (en) * 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030148321A1 (en) 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US20080020990A1 (en) 2003-05-30 2008-01-24 Nippon Shinyaku Co., Ltd. Oligo Double-Stranded Rna Inhibiting the Expression of Bcl-2 and Pharmaceutical Composition Containing the Same
WO2006113747A2 (fr) 2005-04-19 2006-10-26 Prediction Sciences Llc Marqueurs diagnostiques du traitement et de l'evolution du cancer du sein et leurs methodes d'utilisation
US20080280297A1 (en) 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
EP1806359B1 (fr) 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Peptides associeés a des tumeurs et se liantes a des différentes antigènes d'histocompatibilité (HLA) de classe II
WO2007064743A2 (fr) * 2005-11-30 2007-06-07 Cell Signaling Technology, Inc. Reactifs pour la detection de la phosphorylation de proteines dans les voies de signalisation de la leucemie
WO2008103905A2 (fr) 2007-02-23 2008-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticorps qui se lient spécifiquement à irta et son procédé d'utilisation
KR101167392B1 (ko) * 2007-07-27 2012-07-19 이매틱스 바이오테크놀로지스 게엠베하 종양 관련 펩티드의 조성물 및 관련된 항암 백신
GB0721686D0 (en) * 2007-11-05 2007-12-12 Medinnova As Polypeptides
US20110190157A1 (en) 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
EP2409155A1 (fr) 2009-03-15 2012-01-25 Technion Research and Development Foundation, Ltd. Complexes hla solubles utiles pour diagnostiquer des maladies
WO2011035433A1 (fr) 2009-09-23 2011-03-31 University Health Network Souches sélectionnées sur des milieux de croissance exempts de sérum pour analyse protéomique de biomarqueurs du cancer du poumon
WO2014180490A1 (fr) 2013-05-10 2014-11-13 Biontech Ag Prédiction de l'immunogénicité d'épitopes de lymphocytes t
TWI777198B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七）
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers

Also Published As

Publication number Publication date
CL2020002951A1 (es) 2021-02-26
CL2019002878A1 (es) 2020-03-13
PE20191617A1 (es) 2019-11-05
JP2020516313A (ja) 2020-06-11
CL2020002953A1 (es) 2021-03-12
PH12019502300A1 (en) 2020-07-06
US20220362302A1 (en) 2022-11-17
EP3609531A2 (fr) 2020-02-19
CL2020002948A1 (es) 2021-02-26
KR20190137858A (ko) 2019-12-11
CO2019012071A2 (es) 2020-04-01
AU2018253341A1 (en) 2019-11-14
US20220118016A1 (en) 2022-04-21
CL2020002949A1 (es) 2021-02-26
CN110944660A (zh) 2020-03-31
MY197772A (en) 2023-07-13
CR20190509A (es) 2020-01-08
CN111533799A (zh) 2020-08-14
CL2020002952A1 (es) 2021-02-26
SG11201909058WA (en) 2019-10-30
JP7026970B2 (ja) 2022-03-01
CA3059645A1 (fr) 2018-10-18
MX2019012226A (es) 2020-02-07
SG10202100326SA (en) 2021-02-25
IL269813A (en) 2019-11-28
AU2018253341B2 (en) 2022-01-13
CN112521478A (zh) 2021-03-19
US11559550B2 (en) 2023-01-24
BR112019021094A2 (pt) 2020-05-12
SG10202100324YA (en) 2021-02-25
CL2020002950A1 (es) 2021-02-26

Similar Documents

Publication Publication Date Title
MA53680A (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA50925A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA43399A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre la cll et d'autres cancers
MA50542A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
MA43719A (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et d'autres cancers
MA45424A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon à petites cellules et d'autres cancers
MA42494A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA49123A (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers
MA51763A (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du poumon, y compris le cpnpc et d'autres cancers
MA43436A (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 274 - igf-004)
MA43690A (fr) Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
MA49158A (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MA44228A (fr) Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
MA47367A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA51531A (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
MA49100A (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers
IL261786A (en) Peptides and a combination of peptides for use in immunotherapy against types of cancer
MA53326A (fr) Immunothérapie à l'aide de peptides restreints par b*07 et combinaison de peptides contre des cancers et méthodes associées
MA51170A (fr) Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
MA52614A (fr) Peptides destinés à être utilisés en immunothérapie contre des cancers
MA54832A (fr) Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
MA54519A (fr) Immunothérapie à l'aide de peptides restreints par b*08 et combinaison de peptides contre des cancers et méthodes associées
MA46913A (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
ZA201805512B (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
IL262081A (en) New peptides and combinations of peptides for use in immunotherapy for the treatment of acute myeloid leukemia and other cancers